Why the study?
Cardiac disease in sporadic late-onset nemaline myopathy is generally reported as mild and rarely requiring treatment, making severe heart failure as an early, treatable manifestation poorly recognized.
Does standard heart failure medication and autologous stem cell transplantation improve cardiac and muscle function in a patient with sporadic late-onset nemaline myopathy and severe heart failure?
Case Report (n=1)
Does standard heart failure medication and autologous stem cell transplantation improve cardiac and muscle function in a patient with sporadic late-onset nemaline myopathy and severe heart failure?
Answers are grounded in this paper and cite their sources.
Severe heart failure can be an early feature of sporadic late-onset nemaline myopathy and may be reversible with standard heart failure medications and autologous stem cell transplantation.
BACKGROUND: Sporadic late-onset nemaline myopathy (SLONM) is a rare, acquired, adult-onset myopathy, characterized by proximal muscle weakness and the pathognomonic feature of nemaline rods in muscle fibres. Sporadic late-onset nemaline myopathy is associated with cardiac pathology in case reports and small case series, but the severity of cardiac disease is generally mild and rarely requires specific treatment. This case report describes severe heart failure as an early feature of SLONM, which responded to specific treatments, and highlights SLONM as a potentially reversible cause of heart failure. CASE SUMMARY: A 65-year-old woman presented with progressive muscle weakness and a dramatic loss of muscle bulk in her thighs, followed by progressive effort breathlessness over an 18-month period. She required a wheelchair to ambulate. A diagnosis of SLONM was made on histopathological assessment of a muscle biopsy along with electron microscopy. An echocardiogram showed a severely dilated and impaired left ventricle. She was treated with standard heart failure medications and autologous stem cell transplantation, which resulted in improvement of both her cardiac and muscle function, and allowed her to walk again and resume near-normal functional performance status. DISCUSSION: Cardiomyopathy can be a relatively early and life-threatening feature of SLONM and even in severe cases can be effectively treated with standard heart failure medications and autologous stem cell transplantation.
No takes yet. Share an insight, caveat, or question.
Turnquist et al. (2020) conducted a case report in Sporadic late-onset nemaline myopathy (SLONM) with severe heart failure (n=1). Standard heart failure medications and autologous stem cell transplantation was evaluated on Improvement of cardiac and muscle function.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: